Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VGX-6150 · 1 trial · 1 indication
To evaluate the safety and tolerability of VGX-6150 as second-line therapy in chronic hepatitis C patients.
| Arm | Type | Description |
|---|---|---|
| Experimental: 1mg of DNA/dose | EXPERIMENTAL | Subjects will receive a 3 dose series of VGX-6150 containing 1mg DNA/dose administered via IM injection + electroporation at Day 0, Week 4, Week 8, Week 12 |
| Experimental: 3mg of DNA/dose | EXPERIMENTAL | Subjects will receive a 3 dose series of VGX-6150 containing 3mg DNA/dose administered via IM injection + electroporation at Day 0, Week 4, Week 8, Week 12 |
| Experimental: 6mg of DNA/dose | EXPERIMENTAL | Subjects will receive a 3 dose series of VGX-6150 containing 6mg DNA/dose administered via IM injection + electroporation at Day 0, Week 4, Week 8, Week 12 |
| Name | Type | Description |
|---|---|---|
| VGX-6150 | BIOLOGICAL | Plasmid DNA delivered via IM injection with electroporation |
Inclusion Criteria: * Subjects who want to participate in this trial should meet all of the following criteria. 1. Male or females aged 19 to 65 years 2. Chronic hepatitis C patients infected with HCV genotype 1a or 1b 3. Patients who failed\* SOC therapy with PEG-IFN and ribavirin or triple...
VGX-6150 is an investigational monoclonal antibody being developed for the treatment of chronic Hepatitis C infection. It is intended as a second-line therapy for patients with this condition. The drug is currently in clinical development and has not been approved by regulatory authorities.
VGX-6150 is a monoclonal antibody, but its specific molecular target has not been disclosed in available information. The drug is being studied for its safety, tolerability, and immunogenicity in patients with chronic Hepatitis C, indicating it may modulate immune responses, though the exact mechanism remains unspecified.
VGX-6150 is being developed by Inovio Pharmaceuticals, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol INO. The company is conducting clinical research on this investigational monoclonal antibody for chronic Hepatitis C.
VGX-6150 is in Phase 1 clinical development. A Phase 1 trial has been completed, evaluating the safety, tolerability, and immunogenicity of the drug as a second-line therapy for chronic Hepatitis C. The drug remains investigational and is not yet approved for commercial use.
VGX-6150 has been studied in one clinical trial, identified as NCT02027116. This Phase 1 trial, titled 'Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection,' was completed in South Korea with 18 participants.
No alternative names for VGX-6150 have been identified. The drug is known by its code name VGX-6150 and is being developed by Inovio Pharmaceuticals. It is a distinct investigational monoclonal antibody candidate for chronic Hepatitis C.